| ||September 21, 2010|
Pioneer in Islet Transplantation, Dr. James Shapiro, Joins Sernova Scientific Advisory Board
| ||LONDON, ONTARIO--(Marketwire -- September 21, 2010) - Sernova Corp. (TSX-V: SVA), is pleased to announce the appointment of Dr. James Shapiro, MD, Ph.D. FRCS (Eng.) FRCSC, to the Corporation's Scientific Advisory Board. In 2000, Dr. Shapiro led the team responsible for developing the Edmonton Protocol which was a major advancement in the treatment of insulin-dependent diabetes and now the current standard of care for Islet Transplantation.|
"The experience and clinical expertise of Dr. Shapiro will be invaluable to Sernova as it continues to plan its clinical trials program." noted Dr. Philip Toleikis, President & CEO of Sernova Corp.
Dr. Shapiro, a world-renowned transplantation scientist and clinician is Director of the Clinical Islet Transplantation Program at the University of Alberta where he oversees the largest clinical islet transplant program in the world.
Dr. Shapiro's research contributions have been principally focused on improving outcomes of clinical islet transplantation. Under his leadership, an extensive network of international collaborations has been developed to study islet function, and to monitor for tolerance and autoimmune reactivity in the islet recipients receiving immunosuppression. He is Principle Investigator on a number of US National Institutes for Health (NIH) and Juvenile Diabetes Research Foundation (JDRF)-funded clinical trials, including clinical testing of co-stimulation blockade in islet transplantation and he led an international multicentre trial of the Edmonton Protocol.
"I am very impressed with the preclinical assessment of Sernova's Cell Pouch System(tm) and look forward to its clinical application," Said Dr. Shapiro.
Dr. Shapiro has been the recipient of many awards, including a Hunterian Medal from the Royal College of Surgeons of England, the Gold Medal in Surgery from the Royal College of Physicians and Surgeons of Canada, and the Governor General's Gold Medal. He is a recipient of the Meritorious Service Medal from the Governor General of Canada.
He sits on the Editorial Board of the journal Transplantation and Diabetes Therapeutics and Technology, and is an active reviewer for several journals including Nature Medicine, Transplantation, and The British Journal of Surgery.
"The Sernova team is honored by this enormous opportunity to work with such an eminent scientist and leader in the islet transplant field. We are looking forward to having Dr. Shapiro's involvement in the ongoing development of our clinical and regulatory strategy for the Cell Pouch System(tm), added Dr. David White, Chairman of Sernova's Scientific Advisory Board.
Sernova's Cell Pouch System(tm) is a scalable medical device providing a natural "organ-like" environment for therapeutic cells. Once implanted under the skin, it develops into a tissue-engineered pancreas when infused with islets. The natural environment established by the Cell Pouch System(tm) is expected to conserve cell number, and promote natural function thereby increasing cell survival, while significantly increasing the number of treatable patients beyond those with severe disease.
Sernova Corp. is a Canadian-based health sciences company focused on product development and commercialization of innovative proprietary platform medical technologies in the cell therapy arena such as the Cell Pouch System(TM) to provide a safe and efficacious environment for therapeutic cells and Sertolin(TM), a technology which, when combined with cell therapy, may protect therapeutic cells without the need for patients to take anti-rejection drugs.
For further information contact:
Philip Toleikis, Ph.D., President and CEO
Tel: (604) 961-2939
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
The securities offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or any applicable exemption from the registration requirement of such Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.
This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities -- that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
You can view the Next News Releases item: Mon Oct 18, 2010, Sernova Corp Announces Private Placement and $570,000 First Closing
You can view the Previous News Releases item: Mon Sep 13, 2010, Sernova Awarded $275,000 Financial Contribution From NRC-IRAP To Support Research And Development
You can return to the main News Releases page, or press the Back button on your browser.